Vergoeding 2019-2023 voor ATC-subgroep L01EA : Bcr-abl-tyrosinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L01EA01 Imatinib | 9.564.783 | 10.318.671 | 8.709.710 | 2.558.194 | 2.189.532 |
| L01EA02 Dasatinib | 16.917.201 | 15.945.772 | 13.749.055 | 12.486.076 | 4.470.731 |
| L01EA03 Nilotinib | 12.799.088 | 11.488.565 | 9.927.758 | 8.467.679 | 7.672.284 |
| L01EA04 Bosutinib | 2.298.913 | 2.886.077 | 3.304.610 | 3.275.254 | 3.314.493 |
| L01EA05 Ponatinib | 2.220.044 | 2.962.238 | 3.191.722 | 2.507.659 | 2.748.333 |
| L01EA06 Asciminib | . | . | . | . | 1.614.184 |
| Totaal | 43.800.030 | 43.601.324 | 38.882.854 | 29.294.862 | 22.009.558 |